TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.

Tempus AI (TEM) is soaring 13% today after investment bank TD Cowen reinstated coverage of the shares with a Buy rating. TEM ...

TD Cowen analyst Dan Brennan reinstated coverage of Tempus AI (TEM) with a Buy rating and price target of $74, up from $58, following the ...

The stock market extended its winning streak on Wednesday, closing firmer as investors seemed to have already priced in the ...

TD Cowen reinitiated coverage on Tempus AI Inc (NASDAQ:TEM) with a Buy rating, increasing the price target to $74 from a previous target. The stock, currently trading at $61.85, has shown remarkable ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

David R. Epstein, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold 370 shares of the company's Class A Common Stock. The shares were sold on February 3, 2025, at an average price of $53.31 ...

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

Tempus AI, known for its AI-driven precision medicine,... Tuesday - Analysts at TD Cowen have initiated coverage on Tempus AI Inc (NASDAQ:TEM) stock with a Buy rating and have set a price target ...

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) was the recipient of some unusual options trading on Wednesday. Investors bought 51,813 call options on the company. This is an increase of approximately ...

Nancy Pelosi's newest bet saw the purchase of Tempus AI call options — now, a Wall Street analyst has given the stock a new ...

READ NOW: 10 AI Stocks Making Waves on Wall Street and ... On January 21, Bryan Bergin from TD Cowen maintained a Hold rating on UiPath with a price target of $16.00. Several factors associated ...